Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.40 |
| ▸ | ESRRA | P11474 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14850863 | 0.85 | ALDH1A1 (0.56) | ALDH1A1CYP2A6GRM2CYP11B2CYP11B1 | |
| SCHEMBL18934331 | 0.84 | ALDH1A1 (0.54) | ALDH1A1CYP2A6CYP11B2CYP11B1EGLN2 | |
| SCHEMBL26555703 | 0.83 | CYP11B2 (0.44) | ALDH1A1CYP2A6CYP11B2CYP11B1KIF11 | |
| SCHEMBL10094654 | 0.81 | PTGS1 (0.49) | ALDH1A1CYP2A6CYP11B2CYP11B1KIF11 | |
| SCHEMBL30445989 | 0.81 | ESRRA (0.46) | ALDH1A1CYP2A6ESRRA | |
| SCHEMBL139182 | 0.81 | ESRRA (0.46) | ALDH1A1CYP2A6ESRRA | |
| SCHEMBL1046094 | 0.81 | ESRRA (0.46) | ALDH1A1CYP2A6ESRRAMAPK14 | |
| SCHEMBL29306094 | 0.80 | ALDH1A1 (0.50) | ALDH1A1CYP2A6GRM2CYP11B2CYP11B1 | |
| SCHEMBL23624582 | 0.79 | ALDH1A1 (0.54) | ALDH1A1CYP2A6GRM2CYP11B2KIF11 | |
| SCHEMBL7648994 | 0.78 | CYP11B1 (0.46) | CYP11B2CYP11B1EGLN2ESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9704612-B2 | Composition of silver-conjugated compound composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-07-11 | — | — | US | disclosed |
| US-9704612-B2 | Composition of silver-conjugated compound composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-07-11 | — | — | US | disclosed |
| US-9536633-B2 | Metallic composite and composition thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-01-03 | — | — | US | disclosed |
| US-9412487-B2 | Silver-(conjugated compound) composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20120168693-A1 | SILVER-(CONJUGATED COMPOUND) COMPOSITE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120168693-A1 | SILVER-(CONJUGATED COMPOUND) COMPOSITE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120032121-A1 | METALLIC COMPOSITE AND COMPOSITION THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120032121-A1 | METALLIC COMPOSITE AND COMPOSITION THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120032121-A1 | METALLIC COMPOSITE AND COMPOSITION THEREOF | CDH1, EPCAM, CD4 | ALDH1A1 932/4885CYP2A6 3687/4885GRM2 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.